348 related articles for article (PubMed ID: 28606646)
1. Current Use and Trends in Hematopoietic Cell Transplantation in the United States.
D'Souza A; Lee S; Zhu X; Pasquini M
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1417-1421. PubMed ID: 28606646
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic Cell Transplantation after Solid Organ Transplantation.
Doney KC; Mielcarek M; Stewart FM; Appelbaum FR
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2123-2128. PubMed ID: 26271193
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
Kothari A; Ngwube A; Hayashi R; Murray L; Davis J; Haut P; Loechelt BJ; Shenoy S
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1321-5. PubMed ID: 25840334
[TBL] [Abstract][Full Text] [Related]
7. Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplanter?
Hamadani M
Biol Blood Marrow Transplant; 2014 Mar; 20(3):292-4. PubMed ID: 24394802
[No Abstract] [Full Text] [Related]
8. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
[TBL] [Abstract][Full Text] [Related]
9. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
11. Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation.
Kalra A; Williamson T; Daly A; Savoie ML; Stewart DA; Khan F; Storek J
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1654-1663. PubMed ID: 27246372
[TBL] [Abstract][Full Text] [Related]
12. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
13. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
14. Current trends in clinical studies of allogeneic hematopoietic stem cell transplantation.
Pilon S; Jedrysiak D; Sheppard D; Bredeson CN; Tay J; Allan DS
Biol Blood Marrow Transplant; 2015 Feb; 21(2):364-70. PubMed ID: 25445635
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
16. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States.
D'Souza A; Fretham C; Lee SJ; Arora M; Brunner J; Chhabra S; Devine S; Eapen M; Hamadani M; Hari P; Pasquini MC; Perez W; Phelan RA; Riches ML; Rizzo JD; Saber W; Shaw BE; Spellman SR; Steinert P; Weisdorf DJ; Horowitz MM
Biol Blood Marrow Transplant; 2020 Aug; 26(8):e177-e182. PubMed ID: 32438042
[TBL] [Abstract][Full Text] [Related]
17. Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era.
Majhail NS; Chitphakdithai P; Logan B; King R; Devine S; Rossmann SN; Hale G; Hartzman RJ; Karanes C; Laport GG; Nemecek E; Snyder EL; Switzer GE; Miller J; Navarro W; Confer DL; Levine JE
Biol Blood Marrow Transplant; 2015 Jan; 21(1):142-50. PubMed ID: 25445638
[TBL] [Abstract][Full Text] [Related]
18. Admission of hematopoietic cell transplantation patients to the intensive care unit at the Pontificia Universidad Católica de Chile Hospital.
Escobar K; Rojas P; Ernst D; Bertin P; Nervi B; Jara V; Garcia MJ; Ocqueteau M; Sarmiento M; Ramirez P
Biol Blood Marrow Transplant; 2015 Jan; 21(1):176-9. PubMed ID: 25139214
[TBL] [Abstract][Full Text] [Related]
19. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
20. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.
Mevorach D; Zuckerman T; Reiner I; Shimoni A; Samuel S; Nagler A; Rowe JM; Or R
Biol Blood Marrow Transplant; 2014 Jan; 20(1):58-65. PubMed ID: 24140121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
